A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Latest Information Update: 06 Jul 2022
At a glance
- Drugs Atezolizumab (Primary) ; Obinutuzumab; Tazemetostat
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
- Sponsors Roche
- 01 Jul 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia
- 01 Jul 2022 Results published in the Clinical Lymphoma, Myeloma & Leukemia
- 22 Jan 2020 Status changed from active, no longer recruiting to completed.